Skip to Content
Jump to the top of the page

William Blair Thinking

  • Engineering Immune Cells Inside the Body

    By engineering immune cells directly inside a patient, in vivo CAR-T is cutting costs, complexity, and time.

    Read more
  • Building Conviction in a World of Shifting Narratives

    Portfolio Manager Chandan Khanna explains how global markets present a landscape of opportunity for equity investors despite macroeconomic headwinds.

    Read more
  • Q&A With William Blair’s Myles Minter, Named a TipRanks Top 10 Analyst of 2025

    Recently ranked 4th in TipRank's top 10 list of U.S. analysts, Minter reflects on biotech’s inflection point, the themes that defined 2025, and the disciplined framework that guides his approach.

    Read more

Our Mission, Vision, and Values

At William Blair, we're committed to our colleagues, our clients, and our communities. Serving our clients starts with the capabilities and collaboration of our team—making our employees our most important asset. When we create an environment where employees perform their best, our delivery for clients will be the best it can be.

Learn more about our mission, vision, and values

Global Community Partners

We are proud of our signature Global Community Partners program, through which employees nominate organizations to receive catalytic financial support and significant volunteerism opportunities every two years.

More about our community partners

Our Latest News

  • BUNN Has Been Acquired by Ali Group

    William Blair acted as the exclusive financial advisor to BUNN Commercial LP, in connection with its sale to Ali Group.

    Read more
  • BridgeBio Pharma, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of BridgeBio Pharma, Inc. (BBIO $65.36), a commercial-stage biotech company focused on developing medicines for genetic conditions. With this initiation, senior research associate John Boyle, Ph.D. and analyst Myles Minter, Ph.D. have expanded and deepened William Blair’s existing biotechnology coverage.

    Read more
  • Jade Biosciences, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Jade Biosciences, Inc. (JBIO $14.05), a clinical-stage biotechnology company focused on developing novel biologics for the treatment of autoimmune diseases.

    Read more

Join Our Team

Finding, attracting, and developing talented people is the foundation of our success. Learn about the promising career opportunities currently available at William Blair.

Search our job openings
Women sitting outside with a laptop

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures